EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Impaired dopamine release in Parkinson’s disease

Kaitlyn M L Cramb iD, Dayne Beccano-Kelly, Stephanie J Cragg iD, Richard Wade-Martins

Brain · 01.08.2023 · 146 (8) · 3117-3132

DOI: 10.1093/brain/awad064 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Brain, online erschienen am 02.03.2023. Verfasst von Kaitlyn M L Cramb und 3 weiteren Autor:innen. Beteiligte Einrichtung: Oxford Parkinson's Disease Centre and Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, OX1 3QU, UK. Hauptthemen laut MEDLINE: Parkinson Disease, Neurodegenerative Diseases. Die Arbeit wurde bisher 220-mal zitiert (Crossref) und nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Monument Trust Discovery Award from Parkinson’s UK, MJFF, Natural Sciences and Engineering Research Council of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson’s disease is the second most common neurodegenerative disease and yet the early pathophysiological events of the condition and sequences of dysfunction remain unclear. The loss of dopaminergic neurons and reduced levels of striatal dopamine are descriptions used interchangeably as underlying the motor deficits in Parkinson’s disease. However, decades of research suggest that dopamine release deficits in Parkinson’s disease do not occur only after cell death, but that there is dysfunction or dysregulation of axonal dopamine release before cell loss. Here we review the evidence for dopamine release deficits prior to neurodegeneration in Parkinson’s disease, drawn from a large and emerging range of Parkinson’s disease models, and the mechanisms by which these release deficits occur. The evidence indicates that impaired dopamine release can result from disruption to a diverse range of Parkinson’s disease-associated genetic and molecular disturbances, and can be considered as a potential pathophysiological hallmark of Parkinson’s disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseNeurodegenerative DiseasesHumansDopamineDopaminergic Neurons

Stichwörter der Autor:innen

Parkinson’s diseasedopamine releaseneurodegeneration

Substanzen

Dopamine

Autor:innen und Institutionen

  • Oxford Parkinson's Disease Centre and Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, OX1 3QU, UK.
  • Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, 20815, USA.
  • Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, OX1 3QU, UK.

ORCID-Profile: Kaitlyn M L Cramb, Stephanie J Cragg

Förderung

  • Monument Trust Discovery Award from Parkinson’s UK
  • MJFF
  • Natural Sciences and Engineering Research Council of Canada

Zitieren

APA

Cramb, K. M. L., Beccano-Kelly, D., Cragg, S. J., & Wade-Martins, R. (2023). Impaired dopamine release in Parkinson’s disease. Brain, 146(8), 3117-3132. https://doi.org/10.1093/brain/awad064

Vancouver

Cramb KML, Beccano-Kelly D, Cragg SJ, Wade-Martins R. Impaired dopamine release in Parkinson’s disease. Brain. 2023;146(8):3117-3132. doi:10.1093/brain/awad064

BibTeX
@article{Cramb2023,
  author = {Cramb, Kaitlyn M L and Beccano-Kelly, Dayne and Cragg, Stephanie J and Wade-Martins, Richard},
  title = {Impaired dopamine release in Parkinson’s disease},
  journal = {Brain},
  year = {2023},
  volume = {146},
  number = {8},
  pages = {3117--3132},
  doi = {10.1093/brain/awad064}
}
Kostenlos starten →